Trilostane therapy for hyperadrenocorticism in three dogs with adrenocortical metastasis

G. Benchekroun,P. D. Fornel-Thibaud,S. Lafarge,E. Gomez,Dominique Begon,Françoise Delisle,R. Moraillon,Dominique Heripret,C. Maurey,D. Rosenberg
DOI: https://doi.org/10.1136/vr.163.6.190
2008-08-09
Abstract:IN dogs, more than half of the adrenal tumours responsible for hyperadrenocorticism are malignant ([Reusch and Feldman 1991][1]). They can be metastasised by the time of diagnosis or after surgical resection. Medical management is therefore required to control the clinical signs. Trilostane is an
What problem does this paper attempt to address?